Navigation Links
Current Hepatitis C Virus Regimens to Face Stiff Competition with the Launch of Gilead's Sofosbuvir and Janssen/Medivir's Simeprevir
Date:11/21/2013

EXTON, Pa., Nov. 21, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, following the launches of Gilead's sofosbuvir and Janssen/Medivir's simeprevir in the United States, currently marketed triple (Vertex's Incivek- and Merck's Victrelis-containing regimens) and dual therapy hepatitis C virus (HCV) regimens will lose market share to sofosbuvir-and simeprevir-based regimens. When asked about treatment practices in the next six months, surveyed physicians plan to treat 17 percent of their genotype 1 and 21 percent of their actively treated genotype 2/3 HCV patients with a sofosbuvir- and/or simeprevir-containing regimen.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

The report entitled TreatmentTrends®: Hepatitis C Virus (US), Wave 2 also finds that the majority of surveyed physicians reported, unaided, that they are currently warehousing HCV patients in anticipation of new therapies, with nearly 30 percent of this warehousing specifically attributed to waiting for access to sofosbuvir/polymerase inhibitors. While most surveyed physicians are warehousing treatment-naive and treatment-experienced patients as they wait for the approval of simeprevir, sofosbuvir and/or other interferon-free therapy options, only 12 percent of surveyed physicians indicated they are satisfied with currently approved therapies.

"In anticipation of availability of new directly-acting antivirals, the shift in the HCV treatment paradigm is already apparent," said BioTrends Research Group Analyst Sandra Renz. "With the imminent approval of simeprevir and sofosbuvir – agents offering po
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Current Regulatory Expectations Affecting the Validation of Reusable Medical Devices is Subject of Dec. 4th Seminar in Boston
2. U.S. Army Rangers Initiate Groundbreaking Study on Wireless Microcurrent Generating Wound Dressing for Acute Wounds
3. Greater Efficacy on Cognition and Function Over Current Treatments Remain Neurologists Top Unmet Need in Mild to Moderate Alzheimers Disease
4. OPTIMIZERx Corporation Announces the Resignation of the Companys Current CEO & Chairman Mr. Shadron L. Stastney
5. In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
6. Tafinlar in Combination with Mekinist and Nivolumab Have Considerable Efficacy and Tolerability Advantages Over Currently Used Therapies for the Treatment of Unresectable Malignant Melanoma
7. For Moderate to Severe Psoriasis, Thought Leaders Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
8. Nile Therapeutics Announces Filing of Annual and Quarterly Reports to Become Current on SEC Filings
9. Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer
10. Hepatitis C Drug Market: Forecasts for 9 Countries, Players (Current and Future) Analysis in New Research Reports
11. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  The U.S. Department of ... grant to University Hospitals (UH) Case Medical Center Seidman ... national model aimed at improving care for patients with ... the project will test a unique model developed at ... late-stage disease, significant comorbidities, or demonstrated need for high ...
(Date:7/10/2014)... DIEGO , July 10, 2014  RESMED INC. (NYSE: ... its fourth quarter and fiscal year ended June 30, 2014 ... Stock Exchange market close. A press release with ResMed,s results ... the company will host a webcast to discuss operating results ... to begin at 1:30 p.m. US Pacific Time and the ...
(Date:7/10/2014)... LAVAL, Quebec , July 10, 2014  Valeant ... TSX: VRX) today announced it has completed the sale ... Sculptra, and Dysport owned or held by Valeant for ... agreement with Nestle S.A, which recently completed its acquisition ... complete the divestiture of our products to a company ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... 2, 2011 ViroPharma Incorporated (Nasdaq: VPHM ) ... officer of ViroPharma, will present at the Jefferies 2011 Global ... 2011.  The conference is being held in New York City. ... through www.viropharma.com and available for a period of ...
... be presented in a poster at the 2011 Annual Meeting ... in Chicago, Illinois June 3-7 by researchers from The University ... that a laboratory test developed by Biocept, Inc. for the ... Disseminated Tumor Cells (DTCs) can provide potentially valuable information to ...
Cached Medicine Technology:MD Anderson and Biocept Scientists to Present Poster at ASCO on Disseminated Tumor Cells (DTCs) in Bone Marrow and Circulating Tumor Cells (CTCs) in Blood in Early Stage Breast Cancer Patients 2MD Anderson and Biocept Scientists to Present Poster at ASCO on Disseminated Tumor Cells (DTCs) in Bone Marrow and Circulating Tumor Cells (CTCs) in Blood in Early Stage Breast Cancer Patients 3
(Date:7/11/2014)... Volunteers from Scientology Churches and Missions are ... education lectures, forums and conferences, information stands, sports events, ... world. , Drug abuse is an international epidemic. According ... of alcohol and illicit drugs costs more than $425 ... and healthcare. , In the face of statistics ...
(Date:7/11/2014)... 11, 2014 The report, “Specialty ... Applications & Geography - 2018,” defines and segments ... with an analysis and forecast of the volumes ... fibers (Para aramids, meta aramids, UHMW Polyethylene, carbon ... PPS fiber, PBI fiber, PBO fiber, and liquid ...
(Date:7/11/2014)... 11, 2014 Utilizing the Keller Funnel, ... William Koenig, has topped a record number of complication-free ... performed over 400 successful procedures without the occurrence of ... well known across the country for his expertise with ... has long been the foundation for numerous studies and ...
(Date:7/11/2014)... 2014 (HealthDay News) -- Children who have emergency ... complications and potentially even death than those who ... However, the Johns Hopkins researchers noted that ... researchers analyzed data on nearly 440,000 simple emergency ... over a 22-year period. The surgeries are ...
(Date:7/11/2014)... The report “Probiotics Market by Products (Functional ... (Regular, Therapeutic, Preventive Health Care) & Ingredients (Lactobacilli, ... 2019 ” defines and segments the global probiotics ... market value of probiotic products and ingredients. The ... for the global market with an analysis of ...
Breaking Medicine News(10 mins):Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5
... experiences on anti-aging and ... personal beauty, ... public launch of the first consumer website dedicated,to consumer reviews and ... engage in an,open and honest conversation about important decisions that affect ...
... 11:00AM Adults with Attention Deficit Hyperactivity ... Extended-release Tablets showed significant improvements in ADHD symptom ... study results presented today at a major psychiatric ... adolescents with ADHD is clearly established but relatively ...
... Mid-Sized Companies Control Health Care Costs, DALLAS, ... Kenneth H. Cooper, M.D., M.P.H., Cooper Aerobics Enterprises,Inc., ... 37-year,history. Cooper Aerobics Enterprises purchased Health At Work, ... a new division, Cooper Benefits,LLC. Cooper Benefits ...
... have been found in related literature. One extremely rare ... of the World Journal of Gastroenterology because of its ... and sex factors, clinical and histopathological findings, diagnostic methods ... available literature. , The article reported one patient ...
... Ala. University of Alabama at Birmingham (UAB) researchers ... progression and switches on front-to-back body patterning in tadpoles. ... in understanding the complex DNA and cell interplay that ... and other diseases. , The UAB team focused on ...
... AMCS ),announces the following Webcast: (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ... 1, 2007 @ 8:30 AM ET, Where: http://www.videonewswire.com/event.asp?id=43463 ... on to the web at the address ... Inc, 617-779-7892. If you are unable to participate during the ...
Cached Medicine News:Health News:Consumers Open Up on RealSelf.com About 'Getting Work Done' 2Health News:Consumers Open Up on RealSelf.com About 'Getting Work Done' 3Health News:New study of Concerta showed significant improvement of ADHD symptom management in adults 2Health News:An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal 2Health News:An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal 3Health News:An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal 4Health News:The largest colonic lipoma to date 2Health News:Cell pathway, disease linked to histone action 2
... polymerase chain reaction (PCR) to amplify and ... first to fully automate and integrate all ... sample preparation, DNA amplification and detection. Designed ... PCR test results from a raw sample ...
... For use as a non-reactive quality assurance reagent ... Toxoplasma gondii (TOXO IgG and TOXO IgM), IgG ... and rubella IgM), IgG and IgM antibodies to ... IgM antibodies to herpes simplex virus types 1 ...
... a fully automated system with,a disposable ... new refractive procedure known,as Epi-Lasik. The ... epithelium from the,Bowmans membrane leaving a ... the structural integrity,of the stroma and ...
... is a surgical/ mechanical device designed to ... the cornea above Bowman's layer. The Centurion ... used during LASEK to delaminate the epithelium. ... providing a 'minimal-touch' surgical approach, the SES ...
Medicine Products: